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Personalized Risk Assessment in 
Never, Light, and Heavy Smokers in 
a prospective cohort in Taiwan 
Xifeng Wu1,*, Chi Pang Wen2,3,*, Yuanqing Ye1, MinKwang Tsai2,3, Christopher Wen4, 
Jack A. Roth5, Xia Pu1, Wong-Ho Chow1, Chad Huff1, Sonia Cunningham1, Maosheng Huang1, 
Shuanbei Wu2,3, Chwen Keng Tsao6, Jian Gu1,# & Scott M. Lippman7,#
The objective of this study was to develop markedly improved risk prediction models for lung cancer 
using a prospective cohort of 395,875 participants in Taiwan. Discriminatory accuracy was measured 
by generation of receiver operator curves and estimation of area under the curve (AUC). In multivariate 
Cox regression analysis, age, gender, smoking pack-years, family history of lung cancer, personal 
cancer history, BMI, lung function test, and serum biomarkers such as carcinoembryonic antigen (CEA), 
bilirubin, alpha fetoprotein (AFP), and c-reactive protein (CRP) were identified and included in an 
integrative risk prediction model. The AUC in overall population was 0.851 (95% CI = 0.840–0.862), with 
never smokers 0.806 (95% CI = 0.790–0.819), light smokers 0.847 (95% CI = 0.824–0.871), and heavy 
smokers 0.732 (95% CI = 0.708–0.752). By integrating risk factors such as family history of lung cancer, 
CEA and AFP for light smokers, and lung function test (Maximum Mid-Expiratory Flow, MMEF25–75%), 
AFP and CEA for never smokers, light and never smokers with cancer risks as high as those within 
heavy smokers could be identified. The risk model for heavy smokers can allow us to stratify heavy 
smokers into subgroups with distinct risks, which, if applied to low-dose computed tomography (LDCT) 
screening, may greatly reduce false positives.
Lung cancer is the leading contributor to cancer incidence and mortality worldwide1–3. The landmark National 
Lung Screening Trial (NLST) evaluated the benefits of low-dose computed tomography (LDCT) for screening of 
old-aged and heavy smokers (≥ 30 pack-years) and found that annual screening by LDCT yielded a relative reduc-
tion of lung cancer mortality of 20% among those screened when compared to chest radiography, with a caveat of 
potential harms from high false positives, over-diagnoses, economic burden and repeated radiation4. The current 
recommendation for lung cancer screening by LDCT focused mainly on those heavy smokers with at least 30 
pack years. However, not all lung cancer comes from heavy smokers. In fact, it was estimated that only about a 
quarter of currently diagnosed lung cancer patients in the U.S. meet the strict NLST eligibility criteria (age 55–74, 
≥ 30 pack-years smoking history)5. While focusing on heavy smokers is indeed a priority, a substantial portion of 
lung cancer cases continue to occur in light smokers and never smokers.
By design, light smokers and never smokers are not eligible for LDCT screening because they were assumed 
to have too low a risk for lung cancer. However, it is very likely that some of these individuals could have a risk 
of lung cancer similar to heavy smokers. To identify such individuals, additional risk factors working in tandem, 
other than smoking history, will be needed to create accurate risk models within light and never smokers. On 
the other hand, although LDCT could reduce mortality by 20%, the high false positive rate (96.4%) observed 
in the NLST calls for more accurate risk stratification among heavy smokers4. The UK Lung Screening (UKLS) 
Trial became the first trial to set up a threshold for pre-selecting screening population with an estimated risk of 
at least 5% of developing lung cancer in the next 5 years using the Liverpool Lung Project (LLP) risk model6. 
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The American Association for Thoracic Surgery (AATS) guidelines call for annual lung cancer screening with 
LDCT for those starting at age 50 years with a 20 pack-year history if there is an additional cumulative risk of 
developing lung cancer of 5% or greater in the next 5 years7. Over the past decade, a concerted effort has been 
made to develop personalized risk prediction models for lung cancer8. Early reports yielded only modest dis-
criminatory power with an area under the curve (AUC) of 0.72 or lower9–11. More recent models drawing on data 
collected by the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) and the multi-center 
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort which focused on smokers, have 
yielded improved discriminatory power with an AUC of 0.80–0.86 in the modeling population12–14. These existing 
models have primarily incorporated only limited demographic factors (e.g., age, gender, and smoking history) 
and recognized clinical risk variables (e.g., chronic obstructive pulmonary disease (COPD) and pneumonia).
In this study, based on analyzing clinical, biomarker and other (e.g., lung function tests) data from a large 
prospective cohort in Taiwan, we developed integrative lung cancer prediction models for heavy smokers, light 
smokers and never smokers for 5-year and 10-year probability.
Results
Characteristics of Cohort Participants. Among the 395,875 participants, there were a total of 1,117 inci-
dent lung cancer diagnoses. The mean ages were 40.4 for the whole cohort and 60.2 for the lung cancer cases. 
Categorization of the cohort by age group showed that the percentage of lung cancer cases increased from 0.07% 
in those of age < 50 years to 1.95% in those of age ≥ 70 years. Over half (52%) of the cohort was female and 38% 
of the lung cancer cases occurred in females; translating to sex-specific incidences of 0.21% for females and 
0.32% for males. Owing to the high percentage (71%) of never smokers in this cohort, 47% of the lung cancer 
cases occurred in never-smokers. Besides age, gender, and smoking, other variables associated with lung cancer 
included BMI, physical activity, and history of cancer (Table 1 and Supplemental Table 1).
Cox Multivariate Analyses of Laboratory Test and Medical Examination Variables. We selected 
only those variables that were significant based on Cox multivariate regression analysis to develop risk prediction 
models for lung cancer (Supplemental Table 1). Significant risk factors among the laboratory test and medical 
examination variables included low MMEF (0–48 ml/sec versus > 103 ml/sec, HR = 2.26, 95% CI = 1.84–2.78), 
and increasing levels of bilirubin (highest quartile versus lowest quartile, HR = 1.42, 95% CI = 1.19- 1.70), AFP 
(≥ 1.8 ng/ml versus < 1.8 ng/ml, HR = 1.38, 95% CI = 1.12–1.70), CEA (> 7.0 ng/ml versus < 1.5 ng/ml, HR = 7.68, 
95% CI = 6.07–9.73), and CRP (highest versus lowest quartile, HR = 1.55, 95% CI = 1.20–1.99). Serum bilirubin 
displayed a pattern of decreasing risk with increasing quartile levels, reaching a borderline significance when 
comparing the lowest to the highest quartile (HR = 1.16, 95% CI = 0.96 to 1.40). Additional analyses were per-
formed in never smokers, light smokers (pack-years < 30) and heavy smokers (pack-years ≧ 30). The significant 
variables for never smokers include age, gender, BMI, family history of lung cancer, AFP, MMEF, and CEA, the 
significant variables for light smokers include age, sex, smoking status, smoking pack-year, family history of lung 
cancer, AFP, and CEA, and the significant variables for heavy smokers include age, sex, smoking status, smoking 
intensity, BMI, MMEF, and CEA (Table 2).
Risk Modeling. We then developed an integrative risk prediction model for the overall cohort, named the 
MD Anderson – MJ Group Integrative Risk Assessment (MMIRA) model based on variables in Table 2. We 
generated a time-dependent ROC curve, which yielded an AUC of 0.851 (95% CI = 0.840 to 0.862) (Fig. 1). We 
calculated the C-index using internal validation by splitting the overall dataset into equally sized training and 
validation sets (Supplemental Table 2). Concordance was excellent, with only minor attenuation when moving 
from the training set (0.854) to the validation set (0.848) for the overall. We were able to demonstrate good cali-
bration agreement between the observed and predicted probability of no events within the 10-year time frame 
(Supplemental Fig. S1). We also generated separate models in never smokers, light smokers, and heavy smokers 
(Fig. 1). The AUC of 0.806 (95% CI = 0.790 to 0.819) and 0.847 (95% CI = 0.824 to 0.871) showed excellent pre-
dictive power in never-smokers and light smokers. Excellent concordance was also observed with minor atten-
uation from training to validation set for never smokers (0.795 to 0.822), light smokers (0.830 to 0.868), and 
heavy smokers (0.733 to 0.744) (Supplemental Table 2). In addition, we generated separate models in former 
smokers and current smokers with AUCs of 0.873 (95% CI = 0.829 to 0.879) and 0.875 (95% CI = 0.864 to 0.887), 
respectively (Supplemental Fig. S2). Further analysis showed that the positive predictive value for overall, never 
smokers, light smokers, heavy smokers, former smokers, and current smokers were 0.67%, 0.43%, 0.48%, 2.88%, 
1.55%, and 1.73%, respectively (Supplementary Table 3).
Application of risk prediction model. We applied the MMIRA models developed in never smokers, light 
smokers, and heavy smokers to predict probability of developing lung cancer in 5 years and 10 years to hypothet-
ical individuals of age 65 with a range of risk profiles (Fig. 2). For a 65-year old never smoker with relatively low 
risk profile (BMI ≥ 30, negative family history of lung cancer), the predicted risk of developing lung cancer was 
0.11% in 5-years and 0.26% in 10-years. However, the predicted probability of developing lung cancer increased 
to the range of 0.22 to 11.58% in 5-years and the range of 0.51% to 24.86% in 10-years for the addition of one to 
five risk factors (BMI, positive family history of lung cancer, AFP, CEA, and MMEF). Similarly, for a 65-year old 
person who is light smoker, the probability of developing cancer increases from 0.06% to 5.03% in 5 years, and 
from 0.15% to 11.27% in 10 years. For a 65-year old person who is a heavy smoker, the probability of developing 
cancer increases from 0.16% to 3.53% in 5 years, and from 0.42% to 8.82% in 10 years.
We also assigned risk scores to each risk factor based on the strength of the association (Supplementary Table 4). 
The higher HR a risk factor conferred, the higher the risk score was assigned to the risk factor. For example, in 
the age category, age 50–59 was the reference group and the assigned score was 0, age < 50 was protective with an 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:36482 | DOI: 10.1038/srep36482
Variables Level
Overall Never smoking Light smoking Heavy smokers
N = 395,875 LC = 1,117 N = 281,111 LC = 525 N = 90,486 LC = 156 N = 2,4278 LC = 436
N % n % N % n % N % n % N % n %
Age, mean(SD) 40(13.8) 40(13.8) 37(11.3) 57(10.1)
Age < 50 293,040 74% 201 18% 207,061 74% 123 23% 79,619 88% 57 37% 6,360 26% 21 5%
50–59 55,772 14% 260 23% 41,874 15% 146 28% 5,539 6% 26 17% 8,359 34% 88 20%
60–69 34,531 9% 412 37% 23,988 9% 167 32% 3,673 4% 47 30% 6,870 28% 198 45%
≥ 70 12,532 3% 244 22% 8,188 3% 89 17% 1,655 2% 26 17% 2,689 11% 129 30%
Sex Male 191,120 48% 691 62% 92,763 33% 133 25% 75,272 83% 142 91% 23,085 95% 416 95%
 Female 204,755 52% 426 38% 188,348 67% 392 75% 15,214 17% 14 9% 1,193 5% 20 5%
Smoking status Never 281,111 71% 525 47%
Former 23,750 6% 127 11% 18,167 20% 33 21% 5,583 23% 94 22%
Current 89,867 23% 461 41% 71,406 80% 121 79% 18,461 77% 340 78%
Smoking intensity* < 1 86,089 75% 372 63% 76,304 84% 143 92% 9,785 40% 229 53%
(pack/per day) ≥ 1 28,675 25% 220 37% 14,182 16% 13 8% 14,493 60% 207 47%
Pack-year* < 15 66,516 58% 68 11% 66,516 74% 68 44%
15–29.9 23,970 21% 88 15% 23,970 26% 88 56%
≥ 30 24,278 21% 436 74%
BMI (kg/m2) < 25 291,339 74% 781 70% 213,289 76% 362 69% 63,087 70% 101 65% 14,963 62% 318 73%
25–29.9 89,563 23% 312 28% 57,869 21% 147 28% 23,471 26% 53 34% 8,223 34% 112 26%
 ≥ 30 14,801 4% 24 2% 9,842 4% 16 3% 3,884 4% 2 1% 1,075 4% 6 1%
Physical activity Inactive 206,056 52% 546 50% 145,219 52% 240 47% 47,992 53% 78 51% 12,845 53% 228 53%
Low active 89,154 23% 177 16% 65,183 23% 89 17% 20,224 22% 24 16% 3,747 15% 64 15%
Fully active 100,458 25% 374 34% 70,587 25% 186 36% 22,237 25% 50 33% 7,634 32% 138 32%
Family history of lung 
cancer No 379,272 96% 1,059 95% 269,537 96% 497 95% 86,590 96% 146 94% 23,145 95% 416 95%
 Yes 16,603 4% 58 5% 11,574 4% 28 5% 3,896 4% 10 6% 1,133 5% 20 5%
Personal cancer 
history No 390,895 99% 1,091 98% 277,098 99% 512 98% 89,911 99% 155 99% 23,886 98% 424 97%
Yes 4,980 1% 26 2% 4,013 1% 13 2% 575 1% 1 1% 392 2% 12 3%
COPD No 259,217 77% 532 51% 182,532 77% 284 58% 63,322 83% 84 60% 13,363 59% 164 39%
 Yes 20,748 6% 172 16% 13,354 6% 52 11% 4,592 6% 21 15% 2,802 12% 99 24%
 Restricted lung 55,009 16% 346 33% 39,993 17% 156 32% 8,662 11% 36 26% 6,354 28% 154 37%
Lung function
(1) FEV1 (%) 0–61 17,821 5% 143 13% 12,156 5% 42 8% 3,480 4% 15 10% 2,185 9% 86 20%
62–73 26,408 7% 115 11% 19,037 8% 55 11% 5,041 6% 17 11% 2,330 10% 43 10%
74–90 130,574 37% 328 30% 94,443 37% 158 31% 28,851 35% 44 29% 7,280 31% 126 30%
91–105 126,604 35% 301 28% 87,987 35% 157 31% 31,343 38% 47 31% 7,274 31% 97 23%
> 106 55,741 16% 201 18% 38,656 15% 99 19% 12,951 16% 28 19% 4,134 18% 74 17%
(2) MMEF (ml/sec) 0–48 15,598 4% 174 16% 10,113 4% 63 12% 2,927 4% 19 13% 2,558 11% 92 22%
49–54 11,722 3% 61 6% 8,014 3% 23 4% 2,543 3% 8 5% 1,165 5% 30 7%
 55–77 103,091 29% 317 29% 72,785 29% 141 27% 23,397 29% 34 22% 6,909 30% 142 33%
 78–103 147,469 41% 349 32% 105,481 42% 179 35% 34,297 42% 64 42% 7,691 33% 106 25%
 > 103 79,651 22% 193 18% 56,163 22% 109 21% 18,568 23% 27 18% 4,920 21% 57 13%
Bilirubin (mg/dl) M: ≤ 0.68; F ≤ 0.56 100,354 26% 310 28% 66,330 24% 117 23% 26,279 30% 47 31% 7,745 33% 146 34%
M: 0.69–0.87;  
F: 0.57–0.70 95,562 25% 301 27% 67,021 24% 158 30% 22,087 25% 43 28% 6,454 27% 100 23%
M: 0.88–1.11;  
F: 0.71–0.90 97,384 25% 286 26% 70,491 26% 123 24% 21,471 24% 41 27% 5,422 23% 122 28%
M: ≥ 1.12;  
F: ≥ 0.91 93,105 24% 212 19% 70,402 26% 122 23% 18,536 21% 23 15% 4,167 18% 67 15%
AFP (ng/ml) < 1.8 82,806 22% 100 9% 64,516 24% 64 12% 16,862 19% 8 5% 1,428 6% 28 6%
≥ 1.8 299,179 78% 1,000 91% 206,728 76% 450 88% 70,576 81% 147 95% 21,875 94% 403 94%
CEA (ng/ml) < 1.5 253,091 65% 315 28% 200,170 72% 226 43% 47,212 53% 33 21% 5,709 24% 56 13%
1.5–2.5 86,595 22% 298 27% 53,648 19% 138 26% 25,533 29% 49 32% 7,414 31% 111 25%
2.6–4.2 37,278 10% 266 24% 17,968 6% 93 18% 12,514 14% 44 28% 6,796 28% 129 30%
4.3–7.0 10,588 3% 139 12% 4,060 1% 25 5% 3,317 4% 19 12% 3,211 13% 95 22%
> 7.0 2,757 1% 98 9% 993 0% 43 8% 687 1% 10 6% 1,077 4% 45 10%
CRP (mg/L) 0–1 259,145 71% 551 56% 187,169 72% 278 59% 59,607 72% 85 63% 12,369 56% 188 50%
Continued
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assigned score of − 4, whereas the assigned scores for age 60–69 and age ≥ 70 were 2 and 3, respectively. The risk 
scores for all cohort participants ranged from − 4 to 19 for overall cohort: for never smokers, − 5 to 17; for light 
smokers, − 5 to 14; and for heavy smokers, − 3 to 12. Figure 3 depicts the probability of developing lung cancer 
in 5 and 10 years as a function of increasing risk scores. For example, for never smokers with a score of 15, the 
corresponding risk would be 8.42% and 18.48% in 5 and 10 years, respectively (Fig. 3B). Similarly, we could use 
risk scores to stratify light smokers into 20 categories with the 5-year lung cancer probability ranging from 0.00% 
to 7.39% and stratify heavy smokers into 16 categories with the 5-year lung cancer probability ranging from 0.02% 
to 7.48% (Fig. 3C,D).
Discussion
It was estimated that 26.7% of lung cancer cases occurred among heavy smokers who meet NLST eligibility crite-
ria in the U.S.5. The growing desire to extend LDCT screening beyond heavy smokers is understandable, particu-
larly among the overwhelming majority of Asian women who were inflicted with lung cancer but never smoked 
(70% to 90%). In this cohort, more than 70% of lung cancer occurred in female never smokers. These high lung 
cancers in Asian women came mainly from second hand smoke from their fathers, brothers, and spouses, living 
in a small enclosed space, thus the second hand smoking rate could reach 75% in their earlier years throughout 
their life. The LDCT screening results in heavy smokers has elevated the public expectation for targeted screening 
for high-risk groups other than heavy smokers. In this paper, we have developed robust risk prediction models for 
never and light smokers in Asia, in addition to more accurately identify higher risk subjects in heavy smokers. As 
new findings, other than the smoking information and family history, four clinically common biomarkers, CEA, 
AFP, CRP and bilirubin, as well as a specific lung function test, were found to be uniquely useful in identifying 
high risk individuals. These biomarkers and the lung function test divided never smokers, light smokers, and 
heavy smokers into distinct groups with a range of 5-year lung cancer probability. Never-smokers with risk scores 
of 14 and above (Fig. 3C) and light smokers with risk scores of 13 and above would have an absolute cancer risk 
above 5% in five years, a risk threshold level suggested by UKLS and AATS to start the LDCT screening6,7.
There have been attempts to use additional data to improve the discriminative performance of risk stratifica-
tion and participant selection for LDCT screening, most notably the LLP model, which added 4 history questions 
(history of pneumonia, personal history of cancer, asbestos exposure, and family history of lung cancer) and has 
been applied to the UKLS trial. Our study added more risk factors including laboratory biomarkers and a lung 
function test and was able to identify those with cancer risk exceeding the 5% threshold in 5-year probability set 
up by the UKLS and AATS6,7. Our model incorporated several unique predictors of lung cancer risk, including 
MMEF as an index of airway obstruction, and the serum markers CEA, bilirubin, AFP, and CRP. These covariates 
have not been integrated into current lung cancer risk prediction models (Supplemental Table 5) because such 
data are often unavailable for population-based cohort studies.
Spirometry has been used to demonstrate airflow obstruction, and can also suggest restrictive ventilator 
impairment. In lung cancer risk screening, spirometry is particularly valuable among never smokers. Different 
parameters of lung function test have been suggested to evaluate their relationships with lung cancer risks, such 
as COPD, FEV1% or Forced Expiratory Flow in the middle half of FVC (MMEF25–75%). Incremental reduction 
of FEV1 values has been strongly associated with lung cancer risk, independent of smoking15. COPD, as defined 
by the GOLD [Global Initiative for Chronic Obstructive Lung Disease] criteria with FEV1/FVC < 0.7, was also 
known to be a strong risk factor for lung cancer, in both smokers and never smokers. Consistent with the liter-
ature, we found, in our cohort, either FEV1 or COPD a strong risk factor for lung cancer. However, in our final 
comparison among parameters, MMEF25–75% turned out to be the most sensitive indicator for lung cancer risk 
after a multivariate analysis. Therefore, the risk score sheet relied on the values of MMEF25–75% in our modeling. 
The most likely explanation for reduced lung function as a lung cancer risk is that it reflects airway inflamma-
tion, a prodromal phase for lung cancer risk. Airway inflammation could present itself as either obstructive or 
restrictive impairment, with the more impairment the higher the risk. Another possibility is that the reduced lung 
function may impair the ability to clear inhaled carcinogens from their airways, which could lead to increased 
contact time between carcinogens and airway epithelial cells. These mechanisms probably facilitated MMEF25–75% 
as a lung cancer risk not only for smokers but also for never smokers, a feature important in our search for high 
risk individuals among never smokers. In our cohort, the lowest 8% MMEF25–75% of overall subjects had doubled 
their cancer risks and contributed 22% of all lung cancer cases, resulting in a multivariate adjusted HR at 2.06.
The CEA glycoprotein is an established tumor marker for colorectal cancer, and has been evaluated as a prog-
nostic or predictive marker for lung cancer16,17. In our cohort, high CEA, e.g. > 7 ng/ml, showed marked increase 
in lung cancer risk, with adjusted HR 12.82 for never smokers and 4.21 for light smokers. This level of CEA, 
Variables Level
Overall Never smoking Light smoking Heavy smokers
N = 395,875 LC = 1,117 N = 281,111 LC = 525 N = 90,486 LC = 156 N = 2,4278 LC = 436
N % n % N % n % N % n % N % n %
1.1–3 66,919 18% 227 23% 46,419 18% 113 24% 15,002 18% 28 21% 5,498 25% 86 23%
 3,1–10 30,639 8% 132 13% 20,681 8% 53 11% 6,693 8% 13 10% 3,265 15% 66 18%
 > 10 8,499 2% 69 7% 5,537 2% 25 5% 1,900 2% 8 6% 1,062 5% 36 10%
Table 1. Cohort characteristics. LC = lung cancer. BMI = Body mass index. COPD = chronic obstructive 
pulmonary disease. FEV1 = forced expiratory volume in 1 second. MMEF = maximum midexpiratory flow. 
AFP = alpha-fetoprotein. CEA = carcinoembryonic antigen. CRP = C-reactive protein. *Among smokers.
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constituting 1% to 4% of the cohort subjects, served as an excellent screening biomarker in our prediction model. 
The AFP tumor marker is most commonly used to aid screening and diagnosis of liver cancer and monitor 
response to treatment18, but an increased level of AFP has also been associated with other malignancies. In this 
cohort, mild elevation of AFP, ≥ 1.8 ng/ml, was associated with 37% increase in lung cancer among never smokers.
Elevated level of serum CRP, a systemic marker of chronic inflammation, has been consistently associated 
increased risk of lung cancer19,20. With CRP greater than 10 mg/L, lung cancer risk increased by 54% in this 
cohort. For CRP at that level, there were 2% of the cohort and 7% of lung cancer cases.
We had reported the elevated lung cancer risk from low serum bilirubin, which has anti-oxidant properties. 
Others also reported that relatively low serum bilirubin was associated with higher risks of lung cancer and 
AUC
Overall Never Smokers Light Smokers Heavy Smokers
0.851 0.806 0.847 0.732
Variables HR(95% CI) HR(95% CI) HR(95% CI) HR(95% CI)
Age 1.07(1.07–1.08) 1.07(1.06–1.08) 1.08(1.07–1.10) 1.08(1.07–1.09)
Sex Male 0.88(0.74–1.04) 0.71(0.58–0.87) 1.58(0.91–2.77) 1.11(0.71–1.74)
 Female 1.00 1.00 1.00 1.00
Smoking Never 1.00
< 30 pack-year 1.14(0.92–1.42)
≥ 30 pack-year 2.60(2.15–3.14)
Smoking status Former 1.00 1.00
 Current 1.64(1.08–2.48) 1.48(1.16–1.89)
Smoking pack year < 15 1.00
15~30 1.44(1.03–2.02)
Smoking intensity < 1 1.00
 (pack/per day) ≥ 1 1.46(1.20–1.79)
BMI < 25 2.11(1.35–3.30) 1.91(1.13–3.20) 2.48(1.11–5.58)
(kg/m2) 25–29.9 1.79(1.13–2.83) 1.55(0.91–2.64) 2.02(0.89–4.59)
≥ 30 1.00 1.00 1.00
Family history of lung 
cancer No 1.00 1.00 1.00
 Yes 1.44(1.08–1.94) 1.66(1.13–2.45) 2.00(1.05–3.81)
Personal cancer history No 1.00
Yes 1.55(1.02–2.34)
Bilirubin (mg/dl) Male:≤ 0.68;  Female:≤ 0.56 1.16(0.96–1.40)
Male:0.69–0.87; 
Female:0.57–0.70 1.06(0.88–1.29)
 Male:0.88–1.11; Female:0.71–0.90 1.08(0.89–1.31)
 Male:≥ 1.12; Female:≥ 0.91 1.00
AFP (ng/ml) < 1.8 1.00 1.00 1.00
≥ 1.8 1.35(1.08–1.69) 1.37(1.05–1.80) 2.12(1.03–4.33)
MMEF (ml/sec) 0–48 2.00(1.58–2.52) 1.87(1.36–2.57) 2.06(1.47–2.87)
49–54 1.64(1.20–2.26) 1.46(0.93–2.29) 1.71(1.10–2.67)
 55–77 1.49(1.22–1.82) 1.24(0.96–1.60) 1.63(1.19–2.22)
 78–103 1.41(1.16–1.71) 1.19(0.93–1.51) 1.33(0.96–1.83)
 > 103 1.00 1.00 1.00
CEA (ng/ml) < 1.5 1.00 1.00 1.00 1.00
1.5–2.5 1.30(1.09–1.56) 1.24(0.99–1.55) 1.45(0.92–2.28) 1.15(0.83–1.59)
2.6–4.2 1.64(1.35–1.99) 1.82(1.40–2.36) 1.88(1.18–3.01) 1.25(0.91–1.72)
4.3–7.0 2.26(1.79–2.86) 1.76(1.14–2.71) 2.16(1.20–3.89) 1.79(1.27–2.52)
> 7.0 5.70(4.39–7.41) 12.82(9.10–18.07) 5.29(2.55–10.95) 2.55(1.70–3.83)
CRP (mg/L) 0–1 1.00
1.1–3 1.02(0.87–1.20)
 3.1–10 0.96(0.78–1.17)
 > 10 1.38(1.07–1.78)
Table 2. Cox regression lung cancer prediction models from MD Anderson and MJ group Integrative 
Risk Assessment (MMIRA) in overall, never smokers, light smokers, and heavy smokers. BMI = Body mass 
index. AFP = alpha-fetoprotein. MMEF = maximum midexpiratory flow. CEA = carcinoembryonic antigen. 
CRP = C-reactive protein.
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COPD in a cohort study21. This risk remained in our integrative prediction model for the overall group, but not 
subgroups we examined with multivariate analysis.
It is difficult to compare performance metrics between published risk prediction models for lung cancer as 
each have been developed in different populations with varying lengths of follow-up time. In an independent 
case-control study used to compare the early Bach, Spitz and LLP models, differences in model sensitivity and 
specificity were highlighted and only moderate discriminatory power (AUC = 0.66–0.69 for all models) was 
found22. The NLST trial defined high-risk criteria based solely on age and smoking history. It has been estimated 
that if the PLCO risk prediction model had been used to select individuals for LDCT screening in the NLST 
trial, 12 additional deaths attributable to lung cancer could have been prevented14. Using similar calculations, we 
estimate that an additional one death could have been avoided if updated PLCOM2012 model has been used, and 
an additional eight deaths due to lung cancer could have been avoided if our MMIRA model had been applied.
Our models for light smokers (AUC = 0.847) and never-smokers (AUC = 0.808) had excellent predictive 
power. By calculating a risk score based on risk factor profile, the 5-year lung cancer probability of a light smoker 
ranged from 0.00% to over 7.39%, and the probability of a never smoker ranged from 0.01% to over 15.82%. 
Never-smokers with risk scores of 14 and above and light smokers with risk scores of 13 and above would have 
Figure 1. Discriminatory accuracy of lung cancer prediction models from MD Anderson – MJ Group 
Integrative Risk Assessment (MMIRA) in overall, heavy, light and never smokers for lung cancer risk. 
Discriminatory accuracy for predicting lung cancer risk within 10 years was assessed by receiver operator 
characteristics (ROC) analysis calculating area under the curve (AUC).
Figure 2. Application of the integrative risk prediction models in never smokers, light smokers, and heavy 
smokers (smoking pack-year ≥30) to predict absolute risk of developing lung cancer in 5 year and 10 years 
for hypothetical individuals, with different risk profiles by the addition of different risk factors. 
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an absolute cancer risk above 5% in five years, a threshold level suggested by UKLS and AATS to start the LDCT 
screening6,7. Thus, our prediction model is able to stratify light smokers and never smokers into subgroups with 
dramatically different probability of developing lung cancer, with a portion, albeit small, of them as high as those 
in heavy smokers. Clinicians and patients can consult our score sheet in making an informed decision for assess-
ing the risks and benefits of screening with LDCT. As false positives and over-diagnosis had been a problem 
for using LDCT in heavy smokers, so will be the challenges for screening any group other than heavy smok-
ers. However, individuals can make better-informed decisions based on his/her absolute risk of developing lung 
cancer.
Our study has a couple of limitations. First, although we have a relatively high level of discrimination, external 
validation of the models is required to determine predictive ability in an independent population. Nevertheless, 
internal calibration and bootstrap analysis of goodness of fit showed excellent agreement between predicted and 
observed events and between the two randomly selected subcohorts. Secondly, as the MJ model has not been 
validated in a non-Asian population, we do not know if it will function with same predictive power across other 
racial/ethnic groups.
In summary, using a very large prospective cohort of an Asian population, we have demonstrated the power 
of incorporating routine laboratory test data and medical evaluation variables into prediction algorithms for lung 
cancer. Our models should improve selection of high-risk individuals for targeted screening strategies. Additional 
studies are necessary to validate these results in independent cohorts and to extend the findings to other ethnic 
populations.
Methods
Study Population and Data Collection. All subjects were recruited by the MJ Health Group, Taiwan, to 
participate in a national health-screening program. The current analysis was conducted after a median 7.3 years 
(range = 0~11.9 years) of follow-up from 1996 to 2007. Details of the screening program have been reported pre-
viously23. In brief, each subject completed a comprehensive health history questionnaire to collect medical history 
and epidemiological data. Participants underwent hands-on physical examinations and submitted to a panel of 
103 blood and medical tests including lung function tests. Informed consent was obtained from all participants. 
The study was approved by Institutional Review Boards at the National Health Research Institute in Taiwan and 
MD Anderson Cancer Center. All the methods of subject recruitment, data collection, and experiments were 
performed in accordance with relevant guidelines and regulations.
Ascertainment of lung cancer. The national ID of each cohort participant was matched to the National 
Cancer Registry and National Death File in order to assess outcomes and events. As of 2008, the cohort had reg-
istered 1,117 new cases of lung cancer and 799 lung cancer deaths.
Laboratory test and lung function test. Serum biomarkers CEA, bilirubin, AFP, and CRP were tested 
using the Abbott ARCHITECT ci8200. Airway obstruction was measured in a standard spirometry test and 
obstruction expressed as FEV1% or MMEF (maximum mid-expiratory flow).
Figure 3. Predicted probability of lung cancer risk based on the risk scores from MMIRA models (A) in 
overall population, (B) in never smokers, (C) in light smokers, and (D) in heavy-smokers. Blue line – predicted 
probability in 5-year. Red line- predicted probability in 10 year.
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Statistical Analysis. Risk predictors were subjected to stepwise Cox proportional hazards regression anal-
ysis to identify significant predictors in multivariate models. Hazard ratios (HRs) and 95% confidence intervals 
(CIs) were estimated for each variable. Continuous variables, including MMEF, CEA, bilirubin, AFP, and CRP, 
were assessed by quartile or other cut-points as guided by cohort distribution. To evaluate the discriminatory 
accuracy of the risk prediction models, we assessed the goodness of fit by calculating the concordance index 
(C-index) and the area under the curve (AUC) from the receiver operating characteristic (ROC) curve analysis. 
We examined the goodness of fit for 10-year risk prediction in each of the training, validation, and full datasets. 
Bootstrap resampling was performed 100 times to generate the 95% CI for AUC. We created risk scores based on 
weighted sum of the identified risk factors in each model and the weights were based on the coefficients, β i, from 
the multivariate Cox regression model following the procedure by Sullivan et al. 200424. For example, the increase 
in risk associated with a 5-year increase in age was first estimated as the constant B, followed by the calculation of 
risk score rounded to the nearest integer using the β i/B. All statistical tests were two-sided and only P-values less 
than 0.05 were considered statistically significant.
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